CorMedix faces Sept. 23 hearing on settlement of shareholder derivative lawsuits
CRMD•Hearing set on proposed derivative lawsuit settlements
CorMedix faces proposed settlements to end two shareholder derivative suits tied to alleged disclosure failures on DefenCath manufacturing issues in 2019-2022.
Settlement terms call for corporate governance reforms to be adopted or maintained for at least 3.5 years; no cash payments to shareholders.
U.S. District Judge Julien Xavier Neals set a Sept. 23, 2026 hearing in Newark to consider final approval under Rule 23.1.
Plaintiffs’ lawyers plan to seek up to USD 3.9 million in fees and expenses; defendants reserved the right to oppose.
Objections must be filed by Sept. 2, 2026 from holders of common stock as of Jan. 19, 2026.
